StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.96+0.01 (+1.44%)

Close on Nov 17, 2026Market cap $26.64MP/E –Yield –

Inmune Bio cash

Cash and short-term investments held at the end of each period.

Inmune Bio's cash was $18.41M at Jun 30, 2026. For fiscal 2025 it was $24.75M, up 18.3% from the year before. The highest annual figure on record is $74.81M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$24.75M+18.3%
FY2024Dec 31, 2024$20.92M-41.6%
FY2023Dec 31, 2023$35.85M-31.3%
FY2022Dec 31, 2022$52.15M-30.3%
FY2021Dec 31, 2021$74.81M+240.6%
FY2020Dec 31, 2020$21.97M+214.0%
FY2019Dec 31, 2019$7.00M+3657.2%
FY2018Dec 31, 2018$186.20K-86.4%
FY2017Dec 31, 2017$1.37M+867.6%
FY2016Dec 31, 2016$141.66K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$18.41M-44.8%
Q1 FY2026Mar 31, 2026$21.36M+10.5%
Q4 FY2025Dec 31, 2025$24.75M+18.3%
Q3 FY2025Sep 30, 2025$27.73M-17.3%
Q2 FY2025Jun 30, 2025$33.37M+7.4%
Q1 FY2025Mar 31, 2025$19.34M-25.6%
Q4 FY2024Dec 31, 2024$20.92M-41.6%
Q3 FY2024Sep 30, 2024$33.55M-19.8%
Q2 FY2024Jun 30, 2024$31.07M-35.0%
Q1 FY2024Mar 31, 2024$26.00M-49.0%
Q4 FY2023Dec 31, 2023$35.85M-31.3%
Q3 FY2023Sep 30, 2023$41.81M-27.2%
Q2 FY2023Jun 30, 2023$47.83M-21.9%
Q1 FY2023Mar 31, 2023$51.00M-23.6%
Q4 FY2022Dec 31, 2022$52.15M-30.3%
Q3 FY2022Sep 30, 2022$57.41M-32.0%
Q2 FY2022Jun 30, 2022$61.21M+54.9%
Q1 FY2022Mar 31, 2022$66.73M+47.2%
Q4 FY2021Dec 31, 2021$74.81M+240.6%
Q3 FY2021Sep 30, 2021$84.47M+247.5%
Q2 FY2021Jun 30, 2021$39.52M+720.6%
Q1 FY2021Mar 31, 2021$45.34M+664.5%
Q4 FY2020Dec 31, 2020$21.97M+214.0%
Q3 FY2020Sep 30, 2020$24.31M+229.3%
Q2 FY2020Jun 30, 2020$4.82M-48.6%
Q1 FY2020Mar 31, 2020$5.93M-1.9%
Q4 FY2019Dec 31, 2019$7.00M+3657.2%
Q3 FY2019Sep 30, 2019$7.38M+1034.3%
Q2 FY2019Jun 30, 2019$9.36M+744.8%
Q1 FY2019Mar 31, 2019$6.05M+209.2%
Q4 FY2018Dec 31, 2018$186.20K-86.4%
Q3 FY2018Sep 30, 2018$650.86K+359.5%
Q2 FY2018Jun 30, 2018$1.11M–
Q1 FY2018Mar 31, 2018$1.96M–
Q4 FY2017Dec 31, 2017$1.37M–
Q4 FY2016Dec 31, 2016$141.66K–

More Inmune Bio figures

See a number that looks wrong?